In patients with prior ASCVD who are unable to achieve LDL-C levels of 1.8 mmol/L (70 mg/dL) with statins and ezetimibe, treatment with PCSK9 inhibitors is guideline supported for the highest risk patients. This evidence concerns the gene PCSK9 and atherosclerosis.